Chordoma is a rare bone tumor with a known intrinsic heterogeneity. Here, we address this tumor heterogeneity in a new cell culture model for tumor diversity and progression in chordoma. The three cell lines U-CH17P, U-CH17M, and U-CH17S were established from a primary sacral chordoma and its derived metastases, a soft tissue and a skin metastasis, respectively. The lesions had divergent differentiation patterns which are conserved in the derived cell lines making them a suitable in vitro model for the analysis of tumorigenesis in chordoma. A common feature of the three cell lines is the expression of typical chordoma markers, such as Brachyury, vimentin, cytokeratins, EMA and S100 protein. A comparison of the genomic aberrations by array comparative genomic hybridization of the cell lines and the corresponding parental tumor tissues revealed that the precursor cells of U-CH17P, U-CH17M and U-CH17S were already present in the primary tumor. Therefore, we show that clonal diversity of this chordoma exists in the primary tumor and that not all of these subclones tend to metastasize. All cell lines had a CDKN2A loss. A comparison of the gene expression profiles of the cell lines revealed significant differences in the expression of several genes like MAGEC2 and SEMA6A known to be associated with the tendency to metastasize or proliferation and migration. Since the underlying mechanisms of tumor progression in chordoma are still largely unclear, the three U-CH17 cell lines are a suitable in vitro model for elucidating chordoma oncobiology.
. The research was carried out in compliance with the Helsinki Declaration. All experimental protocols were conducted and approved in accordance with the local ethics committee of the University of Ulm (votum for usage of archived human material 03/2014). The patient gave his written informed consent for scientific usage of his tumor cells.
Screening for mycoplasma contamination
Cell lines were tested for mycoplasma contamination using a polymerase chain reaction (PCR) approach (958C for 10 min followed by 55 cycles of 958C, 508C and 688C and final 10 min at 728C) using the OneTaq Quickload 2xMM with GC Buffer (New England Biolabs, Ipswich, MA). The universal mycoplasma primers (Forward: 5 0 -crc ctgrgtagtahrhwcag-3 0 ; Reverse: 5 0 -gcggtgtgtacaarmcccga-3 0 ) were used.
Western blot
For total protein analysis, cells were lysed in Tris-NaCl-Triton-X100-(TNT-) buffer (20 mM Tris [pH 8 .0], 200 mM sodium chloride, 1%-Triton-X100, 1 mM DTT) containing both phosphatase and protease inhibitor cocktails (SigmaAldrich, St. Louis, MO). After an incubation period of 3 min in liquid nitrogen, the lysates were centrifuged at 14,000 rpm at 48C for 15 min. Twenty mg of total protein were separated in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then electro-blotted onto a nitrocellulose membrane applying a semi-dry-method. The following primary antibodies were used: anti-Brachyury (H-210; Santa Cruz, Dallas, TX, 1:1,000) and anti-b-Actin (AC-74; SigmaAldrich, 1:10,000). After incubation with the appropriate secondary horseradish-peroxidase-conjugated antibody, ECL detection of the proteins was performed using the SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Rockford, IL) according to the manufacturer's handbook.
Immunohistochemistry
Immunostaining was performed on formalin-fixed and paraffinembedded tissue sections (3 mm) applying the avidin-biotincomplex-method using the K005 AP/RED Detection System (Dako, Glostrup, Denmark). The following antibodies were used: Brachyury (H-210, Santa Cruz, 1:100), epithelial membrane antigen (EMA) (E29, Dako, 1:500), vimentin (VIM3B4, Dako, 1:300), cytokeratin (AE1 1 AE3, Dako, 1:100), Ki-67 (MIB-1, Dako, 1:200), S100-protein (Dako, 1:1,000). The ratio of positive cells was characterized as follows: "no immunoreactivity detected" (-), "immunoreactivity in up to 30% (1) , "immunoreactivity in >30% and up to 70%" (11) and "immunoreactivity in >70%" (111) of the total number of chordoma cells analyzed. 26 
Array comparative genomic hybridization
Array comparative genomic hybridization (aCGH) was carried out using the SurePrint G3 Human CGH Array 8x60K (Agilent Technologies, Santa Clara, CA). DNA-Isolation of the cell lines was performed using the QiAmp DNA Mini Kit (Qiagen, Hilden, Germany). Quantity and quality of the DNA were assessed on the NanoDrop platform (Thermo Fisher Scientific). DNA hybridization was performed according to the standard procedures after labeling of 500 ng of the sample DNA and the control DNA (Human Reference DNA Female or Human Reference DNA Male, Agilent Technologies). Microarray data was analyzed using Workbench genomics software (Agilent Technologies).
Short tandem repeat analysis
Short tandem repeat (STR) analysis was performed using the GenomeLab STR Primer Set Kit (Beckman Coulter, Krefeld, Germany) and the Amplitaq GOLD DNA Polymerase (Life Technologies, Carlsbad, CA) according to the manufacturer's handbook. PCR products were separated on the CEQ GeXP capillary electrophoresis system (Beckman Coulter) and analyzed using the Gene marker software (Softgenetics, State College, PA).
Gene expression analysis
Expression analyses were performed in biological triplicates. Total RNA was isolated from cell cultures with a time-lag of 2-3 passages between each other to obviate culture and population doubling dependent measurement artifacts. Multiple testings grouped closely together in hierarchical clustering analyses and unsupervised clustering indicating no fundamental cell culture depended changes in the expression patterns of the cell lines. Total RNA was extracted from the cell lines using the RNeasy Mini-Kit (Qiagen). Quality and
What's new?
Chordoma is difficult to study both because of its low incidence and the lack of a suitably complex cell culture model. Here, the authors demonstrate a system that approximates the cellular diversity of this cancer type. They established three cell lines, from a primary chordoma, a skin metastasis and a soft tissue metastasis. Genetic comparison with the parental tumor showed that precursor cells of each line were all present in the primary tumor, suggesting that individual cells within the tumor differ in their genetic propensity to metastasize. This system could be a useful tool for studying how chordomas metastasize.
quantity control was performed using the 2100 Bioanalyzer (Agilent Technologies). Cy-3-labeling and hybridization of the samples were performed according to the Agilent's Onecolor Microarray-based Gene Expression analysis protocol using the Human 4x44K Whole Genome Microarray (Agilent Technologies). Each sample was analyzed in duplicates at least and signals were captured by a SureScan Microarray Scanner (Agilent Technologies). The generated data (GEO accession number: GSE98021) was analyzed using the software Genespring 12.1 (Agilent Technologies) and compared to recently published expression data of 9 sacral chordoma cell lines (GEO accession number: GSE68497). Hierarchical clustering was performed with a euclidean similarity measure and centroid linkage rule. Differentially expressed genes with statistical significance (p values cut-off 0.01) between the two groups (metastases vs. primary tumor) were identified using fold change analysis.
FISH analysis
FISH was performed on formalin-fixed and paraffinembedded tissue sections (2 mm) using the commercially available ZytoLight SPEC CDKN2A/CEN9 Dual Colour Probe (Zytovision, Bremerhaven, Germany), MDM2 12q15/ Cep12 (Zytovision), D3Z1 Biotin-labeled FISH probe (Oncor (Abbott), Chicago, IL) and n-myc 2p24/Cep2 FISH probe (Vysis (Abbott), Chicago, IL) according to the manufacturer's protocol.
Spheroids formation assay
For performing spheroid formation assays, the adherent cells were initially washed with phosphate buffered saline (PBS). Next, the cells were detached using incubation with trypsin/ EDTA for 5 min at 378C. Cells were collected by adding 4 mL of cell culture medium. The cell suspension was transferred to a 15 mL tube and centrifuged for 5 min. Then, the cell pellet was washed twice to remove residual FCS and finally resuspended in 5 mL PBS. About 5,000 cells per well were seeded in a total volume of 500 mL of spheroid formation assay culture medium (DMEM/F12 supplemented with GlutaMAX, serum-free B27-Supplement [Gibco] and recombinant human FGF basic [Novoprotein Scientific inc, Summit, NJ, USA]) in ultra-low attachment 24-well culture plates (Corning, New York, NY). After incubation for 12 days, pictures of the spheroids were taken using a 34 objective lens with Keyence microscope. The total number of spheroids and the spheroid size was measured using the ImageJ software (https://imagej.nih.gov/ij/). For each cell line 5-6 independent experiments were performed.
Colony formation in soft agar
The anchor-independent proliferation of the cell lines U-CH17P, -M and -S was measured by monitoring the growing behavior of the single cells in soft agar following adapted standard protocols. With respect to the specialized culture medium a twofold concentrated mixture of IMDM and RPMI1640 (see the "establishment section") was prepared and mixed with 1% LMP agarose (Thermo Fischer Scientific) to get a final concentration of 0.5% agarose in culture medium. The wells of 6-well cell culture plates were coated with 1.5 mL of this mixture overnight at 48C. The temperature was increased to 378C for 30 min before the cells were seeded. Next, cells of the cell lines were detached, counted and cell suspensions (20,000 cells/mL) were prepared. Equal amounts of the cell suspension and 1% agarose were mixed at 378C to get a 10,000 cell per mL suspension in 0.5% agarose. About 1 mL of this mixture was transferred to each well of the 6-well plates. The mixture was allowed to solidify at room temperature. Then, 200 mL of culture medium was added on top. Considering the slow proliferation of chordoma cells especially when seeded in low densities, the cells were incubated for 49 days at 378C before monitoring the colonies. Twice a week, 100 mL of culture medium was added. After the incubation period, the colonies were counted and the area of the colonies was measured using the ImageJ software. For each cell line six independent experiments were performed.
Cell cycle analysis
Cell cycle analyses were performed using standard protocols. In short, after detaching and washing the cells in PBS (48C) 10 6 to 10 7 cells were resuspended in 1 mL ice cold PBS. Dropwise, 3 mL of ice cold ethanol was added and the cells were incubated on ice for 60 min. Afterwards, the cells were centrifuged and the pellet was resuspended 1 mL of PBS containing propidium iodide and RNaseA. After an incubation of 60 min (at 208C), the cells' DNA content was measured using a FACSCalibur flow cytometer (BD Biosciences, San Jos e, CA). The number of cells in the G0/1-, S-and G2-phase were determined using the Flowing Software 2 (www. flowingsoftware.com). As a control, fibroblasts of a healthy donor at 100% confluency were used. For that the cell line U-CH17P consists of cells with 1 or 2 nuclei in comparable numbers, it is not possible to distinguish between 1 nucleus cells in the G2-and 2 nuclei cells in G0/1-phase. Here, for the calculations it was assumed that the ratio of G0/1 and G2 is comparable in cells with 1 or 2 nuclei.
Proliferation measurement
The proliferation of the cell lines was measured by an MTS assay according to the manufacturer's handbook. Cells of the cell lines U-CH17P, U-CH17M and U-CH17S were seeded in three different densities (6,000, 12,000 or 24,000 cells/cm 2 ) in 96-well flat bottom culture plates. The absorbance (490 nm) was measured in an Epoch multiplate spectrometer (Biotek, Bad Friedrichshall, Germany) at differing time-points up to 286 hr after seeding.
Results

Patient data
The chordoma cell lines were established from a biopsy of the primary tumor and two different metastases of a 38-yearold male Caucasian patient. The residual primary tumor and
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the metastasis tissues were resected 8 weeks after the biopsy was taken. The resected primary tumor measured 22 cm 3 18 cm 3 9.9 cm in size. The metastases (skin metastasis and soft tissue metastasis) were 1.5 and 2.7 cm in diameter, respectively. Before the first biopsy and in the meantime until the tumor resection, the patient did not receive specialized treatment. After tumor resection, the patient received radiotherapy and a systemic therapy with Imatinib. The patient died 9 months after the resection of the tumor.
Characterization of the lesions and the derived cell lines
Histology of the primary tumor was heterogeneous with classical, spindle cell, chondroid and anaplastic areas according to the WHO criteria 24 (Supporting Information Fig. 1 ). The skin metastasis was predominantly of the classical, physaliferous type (not otherwise specified, NOS) while the soft tissue metastasis was of the spindle cell subtype (Figs. 1b and 1c) . All lesions strongly expressed Brachyury (Figs. 1d-1f ). U-CH17P was established from the primary tumor, U-CH17S from the skin metastasis and U-CH17M from the soft tissue metastasis. To reach a pure tumor cell stage, the U-CH17P was cultured for 9 months, the metastasis cells lines were considered as pure cell cultures after 3 months of culturing, respectively. Following guidelines for stable cell lines the cell lines were cultured for >50 population doublings before performing experiments. Short tandem repeats analysis confirmed the different cell lines to origin from the same patient (Supporting Information Table 1 ). All three cell lines were tested negative for mycoplasm contamination. The morphology of the derived cell lines mostly reflects the appearance of the originating tissue. Therefore, the cell lines differ in their shape. U-CH17P and U-CH17M both show a spindle cell- like morphology, especially when reaching high densities in culture. Compared to each other, the single cells of U-CH17P tend to be larger and more prominent (Figs. 1g and 1i) . Furthermore, many cells of U-CH17P have two nuclei while most of the -M cells are mononuclear. The U-CH17S cells appear smaller and less physaliferous than the other lines and grow as a flat cell layer (Fig. 1h) . The expression of Brachyury was conserved (Figs. 1j-1l ). This was also verified by Western blot analysis (Supporting Information Fig. 2) . Comparable to other chordoma cell lines, the population doubling times (PD) of U-CH17P, -M and -S are highly dependent on cell density. Best initial cell densities for optimal growing of the cell lines were found to be 12,000-24,000 cells/cm 2 . In this condition, PDs for U-CH17M and U-CH17S averages to about 3, for U-CH17P to about 6-9 days (Supporting Information Fig. 3 ). In very low densities U-CH17P cells tended to proliferate faster than U-CH17M and -S. But all three cell line needed >10 days to double. All three cell lines have a diploid set of chromosomes as shown by a combination of centromere counting by FISH analyses and comparing total DNA amounts of the tumor cells with control fibroblasts in cell cycle analyses (Supporting Information Fig. 4) . FISH analyses revealed a loss of at least one copy of CDKN2A, known to be typical genomic aberration in chordoma (Supporting Information Table 2 ). Immunocytologically, all cell lines are strongly positive for vimentin and cytokeratins. S100 protein and epithelial membrane antigen (EMA) show varying expressions throughout the three cell lines (Table 1) , indicating distinct differences among the lines. In cell cycle analyses, there are no fundamental differences in the cells' distribution to the cell cycle phases (Supporting Information  Fig. 4) . Only the U-CH17P cells with a single nucleus seem to have a shift of about 10% of the total cells from G0/1-to the S-phase. This may be due to the calculation model needed to estimate the number of mono-and binuclear cells in the combined peak (see methods section). Therefore no significant differences in the cell cycle of the three tumor cell lines can be postulated.
The cell lines U-CH17P, -M and -S are able to form colonies in soft agar and spheroid assays
To determine the cells' clonigenicity and tumorigenicity, growing experiments in soft agar and spheroid formation assays were performed.
The anchorage-independent proliferation capability of the cell lines was tested using soft agar experiments. Although all three cell lines were able to proliferate in soft agar, the parental tumor derived cell line U-CH17P formed significantly more colonies than U-CH17M and U-CH17S (Fig. 2a) . Furthermore, the colonies of U-CH17P were larger in diameter than the other lines (Fig. 2b) . This indicates that the anchorage-independent proliferation of the cell lines is different to the anchorage-dependent proliferation. In the latter, U-CH17P was shown to have longer population doubling times than -M and -S (Supporting Information Fig. 3 ).
In the spheroid formation assays, U-CH17P formed the highest number of spheroids as well. Although U-CH17M and U-CH17S were able to grow in spheroids, too, both cell lines showed significantly lower tendencies to form these threedimensional floating growing structures (Fig. 2c) . However, the spheroids generated by U-CH17M and -S were significantly larger in size (Fig. 2d) . Therefore, all three cell lines are able to form spheroids. The highly increased number of U-CH17P spheroids compared to the metastases derived lines U-CH17M and -S point to a higher number of tumor stem cells within the primary tumor derived cell line. The differing size of the spheroids reflects and confirms the proliferation speed of the cell lines in the classical cell culture. The metastases derived cell lines (U-CH17M and -S) tend to proliferate faster than the cell line derived from the primary tumor (U-CH17P).
We used a genome-wide approach (aCGH) to compare the chromosomal alterations of the cell lines with the corresponding tumor material. The gains and losses of the metastases derived cell lines U-CH17S and U-CH17M fit to the aberrations detected in the originating tissues (Figs. 3a and  3b) . Most of the alterations of the skin metastasis tissue are conserved in U-CH17S, such as gains on chromosomes 1q, 2, 5p, 6, 7, 8, 12, 15, 16, 17, 19, 20q and X. Only small differences exist e.g., additional gains on chromosome 5q, 9, 11p, 13q in the cell line (Fig. 3a) . U-CH17M shows comparable aberrations to the soft tissue metastasis. Only few chromosomes are altered differently, e.g., additional losses in chromosome 9 and 22 in the cell line (Fig. 3b) . Both metastatic cell lines differ in very few copy number changes, namely gains on chromosome 9, 11, 14, 15, 16q and 19q. On the one hand this points to a common origin of the both lines. On the other hand, it shows that the two cell lines are clearly distinguishable from each other on genetic grounds. The primary tumor tissue derived cell line U-CH17P, however, has a very different alteration profile consisting mainly of losses (1p, 3, 4, 9, 10q, 11, 13, 14, 18, 19, 21, 22 and Y). Gains were only detected on 10p and 16 (Fig. 3c) . This indicates capital differences between the primary and the metastatic lines. Comparing the alterations of the primary tumor tissue with those of U-CH17P reveals that, unlike to the metastases lines, the number of aberration overlaps is considerably lower (Fig.  3c) . Nevertheless, nearly all of the losses detected in U-CH17P are present in the corresponding tissue, except losses The results of the immunostaining for the chordoma markers Brachyury, epithelial membrane antigen (EMA), S100-protein, Vimentin and Cytokeratins are given. The protein expression was classified as follows: "no immunoreactivity detected" (-), "immunoreactivity in up to 30% (1), "immunoreactivity in >30% and up to 70%" (11) and "immunoreactivity in >70%" (111) of the total number of chordoma cells analyzed Molecular Cancer Biology on chromosome 9. This points to the existence of different clones within the primary tumor tissue. Therefore, the chromosomal changes of the metastases were compared to those of the primary tumor tissue (Figs. 3d and 3e) . Analyses revealed that all existing gains in primary tumor tissue are covered by the gains of the metastatic cell lines. An overlap of the copy number variations of all three cell lines and the tissue is given in Figure 3f , showing that all genomic alterations of the primary tumor are present in the summarized aberrations detected in the cell lines.
Expression analysis
We performed microarray-based gene expression analysis of the newly established chordoma cell lines. In a hierarchical analysis, the U-CH17 cell lines clearly cluster together in a comparative expression analyses of 12 chordoma cell lines. The close relation between multiple testing of independent probes being isolated from the same line proves the reliability of the expression analyses. The U-CH17 cell lines form a distinct subfamily, proving the closer relation between these lines than to other chordoma cell lines (Fig. 4) . Nevertheless, they can clearly be separated from each other confirming their characteristics as independent cell lines.
Expression fold change analysis reveals significant differences between the primary tumour derived and the metastasis derived lines
Looking for differentially expressed genes in the primary cell line and the metastases lines, a fold change analysis was performed. The 20 most differentially expressed genes between U-CH17P and the metastases lines are given in Table  2 . Highest expressed genes compared to the primary line were found to be the carbonic anhydrase 3 (CA3, 1,600-fold), the melanoma associated antigen C2 (MAGEC2, 500fold) and monoamine oxidase B (MAOB, 400-fold). The lowest downregulated genes in the metastases lines were DLEC1 (deleted in lung and esophageal cancer 1, 190-fold), NTRK2 (neurotrophic receptor tyrosine kinase 2, -140-fold) and PPP2R2B (protein phosphatase 2 regulatory subunit beta, 2130-fold). Thus, striking differences in gene expression of various genes can be found within the tumor progression in vitro model.
Discussion
As chordomas are very rare, the possibility of examining large cohorts is limited. Therefore, the establishment of new chordoma cell lines is crucial to promote the understanding of underlying mechanisms provoking the occurrence of chordomas, their metastases and recurrences. Starting in early 2000, the first chordoma cell line was established. 27 The following two decades, the number was enhanced to >10 lines originating from sacral and clival primary chordomas. 19, [28] [29] [30] Nevertheless, there is a lack of model systems reflecting the complexity of metastatic disease. The U-CH17 model system is a unique example to investigate the basic cellular and genetic background of metastatic chordomas. On a morphological level we show that the isolated cell lines differ in shape fitting to the described heterogeneity of chordomas. 31 This morphological diversity is generally present in the 
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primary tumors but is reduced in metastases which present themselves considerably more homogeneous. This may either be interpreted that chordoma cells are able to switch between different stages by activating distinct pathways or that primary chordomas per se consist of different tumor subclones with differing tendencies to form metastases. We tested these hypotheses by comparing genomic profiles of DNA isolated from tissue of a primary tumor, two metastases of the same patient and the corresponding cell lines established from these tissues by array comparative genomic hybridization. We show that the genomic landscape of gains and losses of genetic material of the metastases cell lines are very similar to those of the corresponding tissue and that the two metastases share many but not all features of genetic variability. By contrast, the comparison of the primary tumor and its derived cell line revealed that only part of the genomic changes detected in the tissue is covered by the changes detected in the cell line. This indicates that the isolated cell line either has lost many of the genetic variations during the establishment or that the primary tumor already consisted of subclones with discriminative genetic alterations. Hence, we compared the gains and losses profile of the primary tumor with those of the metastatic cell lines. Interestingly, the alternations found in these cell lines covered the alterations of the primary tumor that could not be attributed to the primary tumor cell line. Therefore, we postulate the presence of at least three clearly different chordoma clones within the primary tumor. Two of these clones formed metastases in the patient. Thus, the metastases derived cell lines (U-CH17M and U-CH17S) are examples for chordoma clones with higher tendency to metastasize compared to the third line (U-CH17P) originating from the primary tumor.
The tests for anchor-independent cellular growth and tumorigenicity show different tendencies for the differing cell lines. In the soft agar assays, U-CH17P was able to establish more colonies that were as well larger in size than the metastases derived cell lines. This implicates that U-CH17P single cells have a higher capability to survive and rebuild a tumor without being dependent on the tumor's microenvironment. At very low cell densities, U-CH17P cells seemed to proliferate faster compared to the other two lines in standard cell culture. In soft agar assays, the cells are separated to a single cell stage without considerable contact to other cells. Therefore, the larger colonies in soft agar cultivation fit to the U-CH17P cells' tendency to proliferate faster at low seeding densities.
In the spheroid formation experiments, U-CH17P showed a 7-to 10-fold higher ability to form floating and proliferating spheroids compared to U-CH17M and -S. Interestingly, these spherical structures were 3 to 4 times smaller in diameter. This may be regarded as a sign that the primary tumor derived cell line comprises significantly more tumor stem cells being able to enhance their capability to migrate. This points to a higher capability of U-CH17P to form metastases suggesting a parallel progression model in this case of chordoma. Nonetheless, the soft tissue metastasis derived line U-CH17M and the skin metastasis derived line U-CH17S both Figure 4 . Cluster analysis of chordoma cell lines. Hierarchical cluster analysis of the cell lines U-CH17P, U-CH17S and U-CH17M in comparison with nine other sacral chordoma cell lines (U-CH1, U-CH2, U-CH3, U-CH6, U-CH7, U-CH10, U-CH11, U-CH12 and MUGChor1). The cell lines were hybridized using the "Human Whole Genome Microarray 4x44K" (Agilent). Clustering was performed in a Euclidean similarity measure and centroid linkage rule using the software "GeneSpring 12.1" (Agilent). Each cell line was tested at least in duplicates. Differently expressed genes between the two subgroups "primary tumor" (U-CH17P) and "metastases" (U-CH17S and U-CH17M) were identified using fold change filtering (p values cut off: 0.01). The metastases derived cell lines represent the reference group.
were also able to form spheroids. Therefore, there is evidence for a late dissemination and metastatic cascade model of tumor progression as well. In aCGH analyses of DNA isolated from tissue consisting of different clones, the result is a summarized profile. In such a profile, copy number changes only existing in one clone are clearly represented. In the profile of the copy number changes of the primary tumor, most of the striking genomic aberrations of the three established cell lines are clearly detectable as gains detected on the chromosomes 1q, 6, 7, 8, 19, 20 and X as well as losses on the chromosomes 1p, 3, 4, 10, 11, 13, 14, 15, 18 and 21.
Opposed changes in copy numbers complement to a misleading normal signal in summarized aCGH profiles. U-CH17S shows distinct gains on chromosome 9 whereas U-CH17M and U-CH17P have losses on this chromosome. In the profile of DNA of the primary tumor tissue chromosome 9 seems to have no copy variations. This may be seen as summarized opposing copy changes of the underlying clones. However, FISH analyses revealed at least a loss of CDKN2A which is a genetic hallmark in chordoma. 19, 32 Interestingly, U-CH17M and U-CH17S have clear gains of one copy of chromosome 12, whereas the primary tumor tissue profile and U-CH17P both do not show any copy number variation of this chromosome. This implicates the existence of another chordoma clone being similar to the clones established as cell lines but harboring a chromosome 12 loss as unique chromosomal marker. Our findings point out that the heterogeneity of primary chordoma is due to subclones that indeed are related to but nevertheless clearly distinguishable from each other.
In 2014, El-Heliebi et al. were able to show that the morphological different subentities in primary chordomas and morphological differing individual cells of chordoma cell lines can be classified by a differing expression of several genes. 31 This was interpreted as a pathway activating switch within the tumor or tumor cell line, respectively. However, this does not exclude the possibility of a mixture of distinct clones. We performed an expression profiling of the three U-CH17 cell lines and compared them among each other and with nine other chordoma cell lines. An unsupervised hierarchical clustering revealed that the U-CH17 cell lines cluster together implicating a closer relationship than to other chordoma cell lines. Therefore, although being closer related than lines originating from other chordomas, the U-CH17 lines are clearly differing from each other by diverging expression of various genes. Thus, we were interested in the genes being possibly involved in metastasizing. Therefore, we grouped the lines U-CH17S and U-CH17M and tested for expression differences to the cell line U-CH17P. Several genes that have previously been described to have influence on tumor growth, migration of tumor cells or genes that have commonly been correlated to metastatic disease were found to be highly dysregulated in the cell lines originating from metastasis. Carbonic anhydrase III (CA3), of which the expression was proven to have an impact on cellular growth and invasiveness in SK-Hep1 hepatoma cells, 33 shows a more than 1,000-fold upregulation in the metastasis lines compared to the primary chordoma cell line U-CH17P. Other highly upregulated genes as MAGEC2 and DSCR8 are known to be involved in metastatic disease in breast carcinoma and melanoma, respectively. 34, 35 Downregulation of DLEC1 was found in squamous cell carcinoma, prostate adenocarcinoma and lymphomas [36] [37] [38] whereas secreted frizzled-related protein 4 downregulation was correlated with reduction of apoptosis. 39 The finding of these dysregulated genes among others directly related to cancer or cancer-related mechanisms as migration, proliferation and apoptosis buttress the usability of U-CH17 as a cancer progression model in chordoma to enlighten the so far unknown mechanisms of metastasizing and progression in this rare tumor entity.
